Agilent Technologies (Santa Clara, California, USA) and Metrohm (Herisau, Switzerland) have announced that they have entered into a non‑exclusive agreement that means that Metrohm are a value-added reseller for Agilent single- and triple-quadrupole mass spectrometers as well as inductively coupled plasma–mass spectrometry (ICP-MS) products, software, and services in France, Spain, Switzerland, UK, and Ireland. This partnership expands the ion chromatography (IC) capabilities of Metrohm. For more information, please visit: www.agilent.com
Waters Corporation (Milford, Massachusetts, USA) has announced it has completed its acquisition of Wyatt Technology (Santa Barbara, California, USA). “We are pleased to complete the acquisition of Wyatt, which is a significant milestone for Waters as we advance our strategy to accelerate value creation and generate faster growth,” said Dr. Udit Batra, President and CEO, Waters Corporation. “With Wyatt, we are even better positioned to solve our customers’ critical challenges with differentiated bioanalytical characterization techniques. We welcome the Wyatt team to Waters and look forward to facilitating a smooth integration process and working together to deliver an unmatched set of bioanalytical characterization solutions to our global customers.” For more information, please visit: www.waters.com
RAFA 2024 Highlights: Contemporary Food Contamination Analysis Using Chromatography
November 18th 2024A series of lectures focusing on emerging analytical techniques used to analyse food contamination took place on Wednesday 6 November 2024 at RAFA 2024 in Prague, Czech Republic. The session included new approaches for analysing per- and polyfluoroalkyl substances (PFAS), polychlorinated alkanes (PCAS), Mineral Oil Hydrocarbons (MOH), and short- and medium-chain chlorinated paraffins (SCCPs and MCCPs).
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.